Basket

Record was added to the basket

1.Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE"

Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE" / Sufliarsky J. . Onkológia. - ISSN 1336-8176 . - Roč. 12, č. 5 (2017), s. 379

C 3069
Request a copy DDS
DSD service
From the basket
Citation
Bookmark

Selected documents
Citation

citace PRO
article

For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.